MEDI:GATE NEWS Macrogen’s first cash dividend decision since its inception… Efforts to enhance shareholder value

Macrogen is the first to decide on cash dividends since its inception and to improve shareholder value. Macrogen announced on the 4th that it has decided on a cash dividend of 300 won per common share.

The market price dividend rate is 1.2%, and the total dividend amount is about 3 billion won. The reference date for dividends is the last day of last year.

Macrogen’s dividend payment was decided to meet market expectations and increase shareholder value based on the highest performance since its inception.

Macrogen announced on the 16th that its operating profit in 2020 was KRW 7.2 billion, an increase of 899% compared to the previous year, and net income was KRW 90.8 billion, a 778% increase from the previous year through a 30% change disclosure.

Despite the Corona 19 crisis last year, the DNA sequencing business, a core business at home and abroad, achieved stable sales growth and operated in new businesses such as the single cell business, which analyzes single cells of cancer tissues, and the microbiome business, which analyzes microbial communities and intestinal microbes. By realizing profits, performance grew.

Macrogen CEO Soo-Kang Lee said, “We decided to pay dividends in cash to share our performance with our shareholders even in the difficult external environment where the domestic and overseas economic downturn continues due to the prolonged Corona 19.” Macrogen, which has achieved this, plans to focus on investment in R&D and expansion of new businesses, and will do its best to increase corporate value.”